Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Company Overview - Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing combination medicines targeting chronic conditions, including obstructive sleep apnea (OSA) [6] - The company is advancing novel oral fixed-dose treatments based on evidence-based innovation, with lead programs including IHL-42X, IHL-675A, and PSX-001 [6] Appointment of Dr. Alison Wimms - Dr. Alison Wimms has been appointed as an advisor to Incannex's newly formed IHL-42X OSA Clinical Advisory Board, representing ResMed [1][3] - Dr. Wimms brings over 20 years of experience in the sleep medicine industry and holds a Ph.D. in Medicine, a Master of Medicine in Sleep Medicine, and a Bachelor of Science from the University of Sydney [2] IHL-42X Clinical Development - IHL-42X is an oral fixed-dose combination of acetazolamide and dronabinol, currently in Phase 2/3 clinical studies for OSA treatment [4] - The drug targets two physiological pathways associated with intermittent hypoxia and hypercapnia, which are characteristic of OSA [4] - In a prior Australian Phase 2 trial, IHL-42X reduced the Apnea-Hypopnea Index (AHI) by an average of 51% relative to baseline at the lowest dose [4] - The ongoing global Phase 2/3 'RePOSA' clinical trial is evaluating IHL-42X in individuals with OSA who are non-compliant, intolerant, or naïve to positive airway pressure devices, with a top-line readout expected in the first half of 2025 [4]